Gamida Cell Ltd - ESG Rating & Company Profile powered by AI
Other corporations in the scoring industry group for Gamida Cell Ltd are displayed below. This Disclosure score includes 17 United Nations SDGs including: 'Good Health & Wellbeing', 'Industry, Innovation & Infrastructure' and 'Partnerships for the Goals'. The SDG score for Gamida Cell Ltd represents the company's transparency towards the United Nations SDGs.
Gamida Cell Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.9; made up of an environmental score of 8.0, social score of 3.2 and governance score of 6.4.
5.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 498 | Redx Pharma PLC | 6.0 | High |
| 498 | Vimta Labs Ltd | 6.0 | High |
| 521 | Gamida Cell Ltd | 5.9 | High |
| 521 | Cellink AB | 5.9 | High |
| 521 | Celon Pharma SA | 5.9 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Gamida Cell Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Gamida Cell Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Gamida Cell Ltd report the average age of the workforce?
Sign up for free to unlockDoes Gamida Cell Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Gamida Cell Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Gamida Cell Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Gamida Cell Ltd offer flexible work?
Sign up for free to unlockDoes Gamida Cell Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Gamida Cell Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Gamida Cell Ltd conduct supply chain audits?
Sign up for free to unlockDoes Gamida Cell Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Gamida Cell Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Gamida Cell Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Gamida Cell Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Gamida Cell Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Gamida Cell Ltd disclose water use targets?
Sign up for free to unlockDoes Gamida Cell Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Gamida Cell Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Gamida Cell Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Gamida Cell Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Gamida Cell Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Gamida Cell Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Gamida Cell Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Gamida Cell Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Gamida Cell Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Gamida Cell Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Gamida Cell Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Gamida Cell Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Gamida Cell Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Gamida Cell Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Gamida Cell Ltd disclose its waste policy?
Sign up for free to unlockDoes Gamida Cell Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Gamida Cell Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Gamida Cell Ltd disclose energy use targets?
Sign up for free to unlockDoes Gamida Cell Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Gamida Cell Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Gamida Cell Ltd
These potential risks are based on the size, segment and geographies of the company.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.